SARS-CoV-2 spike S2-specific neutralizing antibodies

References

• Brix TH, Hegedus L. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and thyroid disease. An update. Curr Opin Endocrinol Diabetes Obes. 2021;28:525–532. doi:10.1097/MED.0000000000000654
   PubMedGoogle Scholar
• Paim FC, Bowman AS, Miller L, et al. Epidemiology of deltacoronaviruses (delta-CoV) and gammacoronaviruses (gamma-CoV) in wild birds in the United States. Viruses. 2019;11.
   PubMed Web of Science ®Google Scholar
• Barnes CO, West AP, Huey-Tubman KE, et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. Cell. 2020;182:828–842. doi:10.1016/j.cell.2020.06.025
   PubMed Web of Science ®Google Scholar
• Mesel-Lemoine M, Millet J, Vidalain PO, et al. A human coronavirus responsible for the common cold massively kills dendritic cells but not monocytes. J Virol. 2012;86:7577–7587. doi:10.1128/JVI.00269-12
   PubMed Web of Science ®Google Scholar
• Shrestha LB, Tedla N, Bull RA. Broadly-neutralizing antibodies against emerging SARS-CoV-2 variants. Front Immunol. 2021;12 752003. doi:10.3389/fimmu.2021.752003
   PubMed Web of Science ®Google Scholar
• Yi Y, Lagniton PNP, Ye S, et al. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci. 2020;16:1753–1766. doi:10.7150/ijbs.45134
   PubMed Web of Science ®Google Scholar
• Yang WT, Huang WH, Liao TL, et al. SARS-CoV-2 E484K mutation narrative review: epidemiology, immune escape, clinical implications, and future considerations. Infect Drug Resist. 2022;15:373–385. doi:10.2147/IDR.S344099
   PubMed Web of Science ®Google Scholar
• Li Q, Nie J, Wu J, et al. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell. 2021;184:2362–2371. doi:10.1016/j.cell.2021.02.042
   PubMed Web of Science ®Google Scholar
• Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell. 2021;184:2348–2361. doi:10.1016/j.cell.2021.02.037
   PubMed Web of Science ®Google Scholar
• Garcia-Beltran WF, Lam EC, St Denis K, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184:2372–2383. doi:10.1016/j.cell.2021.03.013
   PubMed Web of Science ®Google Scholar
• Lamers MM, Haagmans BL. SARS-CoV-2 pathogenesis. Nat Rev Microbiol. 2022;20:270–284. doi:10.1038/s41579-022-00713-0
   PubMed Web of Science ®Google Scholar
• Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol. 2020;41:1100–1115. doi:10.1016/j.it.2020.10.004
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263. doi:10.1126/science.abb2507
   PubMed Web of Science ®Google Scholar
• Li X, Yuan H, Li X, et al. Spike protein mediated membrane fusion during SARS-CoV-2 infection. J Med Virol. 2023;95:e28212.
   PubMed Web of Science ®Google Scholar
• Akinosoglou K, Schinas G, Gogos C. Oral antiviral treatment for COVID-19: a comprehensive review on nirmatrelvir/ritonavir. Viruses. 2022;14.
   Web of Science ®Google Scholar
• Wong CKH, Au ICH, Lau KTK, et al. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis. 2022;22:1681–1693. doi:10.1016/S1473-3099(22)00507-2
   PubMed Web of Science ®Google Scholar
• Piepenbrink MS, Park JG, Deshpande A, et al. Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a spike S2 domain-specific human neutralizing monoclonal antibody. PLoS Pathog. 2022;18:e1010691. doi:10.1371/journal.ppat.1010691
   PubMed Web of Science ®Google Scholar
• Li D, Sempowski GD, Saunders KO, et al. SARS-CoV-2 neutralizing antibodies for COVID-19 prevention and treatment. Annu Rev Med. 2022;73:1–16. doi:10.1146/annurev-med-042420-113838
   PubMed Web of Science ®Google Scholar
• Tso FY, Lidenge SJ, Poppe LK, et al. Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma. PLoS One. 2021;16:e0247640.
   PubMed Web of Science ®Google Scholar
• McCreary EK, Kip KE, Collins K, et al. Evaluation of bebtelovimab for treatment of COVID-19 during the SARS-CoV-2 omicron variant era. Open Forum Infect Dis. 2022;9:ofac517. doi:10.1093/ofid/ofac517
   PubMed Web of Science ®Google Scholar
• Keam SJ. Tixagevimab + Cilgavimab: first approval. Drugs. 2022;82:1001–1010. doi:10.1007/s40265-022-01731-1
   PubMed Web of Science ®Google Scholar
• Dickey TH, Tang WK, Butler B, et al. Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response. Sci Adv. 2022;8:eabq8276. doi:10.1126/sciadv.abq8276
   PubMed Web of Science ®Google Scholar
• Flahault A, Touchard J, Pere H, et al. Breakthrough omicron COVID-19 infections in patients receiving the REGEN-Cov antibody combination. Kidney Int. 2022;101:824–825. doi:10.1016/j.kint.2022.01.016
   PubMed Web of Science ®Google Scholar
• Takashita E, Yamayoshi S, Simon V, et al. Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med. 2022;387:468–470. doi:10.1056/NEJMc2207519
   PubMed Web of Science ®Google Scholar
• Olukitibi TA, Ao Z, Warner B, et al. Significance of conserved regions in coronavirus spike protein for developing a novel vaccine against SARS-CoV-2 infection. Vaccines (Basel). 2023;11.
   PubMed Web of Science ®Google Scholar
• Pinto D, Sauer MM, Czudnochowski N, et al. Broad betacoronavirus neutralization by a stem helix-specific human antibody. Science. 2021;373:1109–1116. doi:10.1126/science.abj3321
   PubMed Web of Science ®Google Scholar
• Zhou P, Yuan M, Song G, et al. A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. Sci Transl Med. 2022;14:eabi9215. doi:10.1126/scitranslmed.abi9215
   PubMed Web of Science ®Google Scholar
• Hurlburt NK, Homad LJ, Sinha I, et al. Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit. Commun Biol. 2022;5:342. doi:10.1038/s42003-022-03262-7
   PubMed Web of Science ®Google Scholar
• Wang C, van Haperen R, Gutierrez-Alvarez J, et al. A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies. Nat Commun. 2021;12:1715. doi:10.1038/s41467-021-21968-w
   PubMed Web of Science ®Google Scholar
• Walls AC, Tortorici MA, Snijder J, et al. Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion. Proc Natl Acad Sci U S A. 2017;114:11157–11162. doi:10.1073/pnas.1708727114
   PubMed Web of Science ®Google Scholar
• Cai Y, Zhang J, Xiao T, et al. Distinct conformational states of SARS-CoV-2 spike protein. Science. 2020;369:1586–1592. doi:10.1126/science.abd4251
   PubMed Web of Science ®Google Scholar
• Shrock E, Fujimura E, Kula T, et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science. 2020;370. doi:10.1126/science.abd4250
   PubMed Web of Science ®Google Scholar
• Ladner JT, Henson SN, Boyle AS, et al. Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. Cell Rep Med. 2021;2:100189. doi:10.1016/j.xcrm.2020.100189
   PubMedGoogle Scholar
• Shi W, Wang L, Zhou T, et al. Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability. Structure. 2022;30:1233–1244. doi:10.1016/j.str.2022.06.004
   PubMed Web of Science ®Google Scholar
• Li CJ, Chao TL, Chang TY, et al. Neutralizing monoclonal antibodies inhibit SARS-CoV-2 infection through blocking membrane fusion. Microbiol Spectr. 2022;10:e0181421.
   PubMed Web of Science ®Google Scholar
• Sauer MM, Tortorici MA, Park YJ, et al. Structural basis for broad coronavirus neutralization. Nat Struct Mol Biol. 2021;28:478–486. doi:10.1038/s41594-021-00596-4
   PubMed Web of Science ®Google Scholar
• Hsieh CL, Werner AP, Leist SR, et al. Stabilized coronavirus spike stem elicits a broadly protective antibody. Cell Rep. 2021;37:109929. doi:10.1016/j.celrep.2021.109929
   PubMed Web of Science ®Google Scholar
• Dacon C, Peng L, Lin TH, et al. Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses. Cell Host Microbe. 2023;31:97–111. doi:10.1016/j.chom.2022.10.010
   PubMed Web of Science ®Google Scholar
• Seow J, Graham C, Hallett SR, et al. Chadox1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants. Cell Rep. 2022;39:110757. doi:10.1016/j.celrep.2022.110757
   PubMed Web of Science ®Google Scholar
• Amanat F, Thapa M, Lei T, et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell. 2021;184:3936–3948. doi:10.1016/j.cell.2021.06.005
   PubMed Web of Science ®Google Scholar
• Song G, He WT, Callaghan S, et al. Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. Nat Commun. 2021;12:2938. doi:10.1038/s41467-021-23074-3
   PubMed Web of Science ®Google Scholar
• Deshpande A, Schormann N, Piepenbrink MS, et al. Structure and epitope of a neutralizing monoclonal antibody that targets the stem helix of β coronaviruses. bioRxiv. 2022;2022.09.14.507947.
   Google Scholar
• Zhou P, Song G, Liu H, et al. Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. Immunity. 2023;56:669–686. doi:10.1016/j.immuni.2023.02.005.
   Web of Science ®Google Scholar
• Ullah I, Prevost J, Ladinsky MS, et al. Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. Immunity. 2021;54:2143–2158. doi:10.1016/j.immuni.2021.08.015
   PubMed Web of Science ®Google Scholar
• Jennewein MF, MacCamy AJ, Akins NR, et al. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. Cell Rep. 2021;36:109353. doi:10.1016/j.celrep.2021.109353
   PubMed Web of Science ®Google Scholar
• Li W, Chen Y, Prevost J, et al. Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern. Cell Rep. 2022;38:110210. doi:10.1016/j.celrep.2021.110210
   PubMed Web of Science ®Google Scholar
• Vanderheijden N, Stevaert A, Xie J, et al. Functional analysis of human and feline coronavirus cross-reactive antibodies directed against the SARS-CoV-2 fusion peptide. Front Immunol. 2021;12:790415. doi:10.3389/fimmu.2021.790415
   PubMed Web of Science ®Google Scholar
• Morgenlander WR, Henson SN, Monaco DR, et al. Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality. J Clin Invest. 2021;131. doi:10.1172/JCI146927
   PubMed Web of Science ®Google Scholar
• Wang H, Wu X, Zhang X, et al. SARS-CoV-2 proteome microarray for mapping COVID-19 antibody interactions at amino acid resolution. ACS Cent Sci. 2020;6:2238–2249. doi:10.1021/acscentsci.0c00742
   PubMed Web of Science ®Google Scholar
• Ng KW, Faulkner N, Cornish GH, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020;370:1339–1343. doi:10.1126/science.abe1107
   PubMed Web of Science ®Google Scholar
• Poh CM, Carissimo G, Wang B, et al. Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients. Nat Commun. 2020;11:2806. doi:10.1038/s41467-020-16638-2
   PubMed Web of Science ®Google Scholar
• Sun X, Yi C, Zhu Y, et al. Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2. Nat Microbiol. 2022;7:1063–1074. doi:10.1038/s41564-022-01155-3
   PubMed Web of Science ®Google Scholar
• Ge J, Wang R, Ju B, et al. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry. Nat Commun. 2021;12:250. doi:10.1038/s41467-020-20501-9
   PubMed Web of Science ®Google Scholar
• Dacon C, Tucker C, Peng L, et al. Broadly neutralizing antibodies target the coronavirus fusion peptide. Science. 2022;377:728–735. doi:10.1126/science.abq3773
   PubMed Web of Science ®Google Scholar
• Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021;592:616–622. doi:10.1038/s41586-021-03324-6
   PubMed Web of Science ®Google Scholar
• Low JS, Jerak J, Tortorici MA, et al. ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies. Science. 2022;377:735–742. doi:10.1126/science.abq2679
   PubMed Web of Science ®Google Scholar
• Wu WL, Chiang CY, Lai SC, et al. Monoclonal antibody targeting the conserved region of the SARS-CoV-2 spike protein to overcome viral variants. JCI Insight. 2022;7.
   Web of Science ®Google Scholar
• Xia S, Zhu Y, Liu M, et al. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol; 2020(17):765–767.
   Google Scholar
• Ling R, Dai Y, Huang B, et al. In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2. Peptides. 2020;130:170328. doi:10.1016/j.peptides.2020.170328
   PubMed Web of Science ®Google Scholar
• Elshabrawy HA, Coughlin MM, Baker SC, et al. Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing. PLoS One. 2012;7:e50366. doi:10.1371/journal.pone.0050366
   PubMed Web of Science ®Google Scholar
• Lai SC, Chong PC, Yeh CT, et al. Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV). J Biomed Sci. 2005;12:711–727. doi:10.1007/s11373-005-9004-3
   PubMed Web of Science ®Google Scholar
• Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369:1014–1018. doi:10.1126/science.abd0831
   PubMed Web of Science ®Google Scholar
• Nguyen H, Lan PD, Nissley DA, et al. Cocktail of REGN antibodies binds more strongly to SARS-CoV-2 than its components, but the omicron variant reduces its neutralizing ability. J Phys Chem B. 2022;126:2812–2823. doi:10.1021/acs.jpcb.2c00708
   PubMed Web of Science ®Google Scholar
• Convertino I, Ferraro S, Cappello E, et al. Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence. Expert Opin Drug Discov. 2023;18:231–245. doi:10.1080/17460441.2023.2170348
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383:2603–2615. doi:10.1056/NEJMoa2034577
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–416. doi:10.1056/NEJMoa2035389
   PubMed Web of Science ®Google Scholar
• Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516–527. doi:10.1038/s41586-020-2798-3
   PubMed Web of Science ®Google Scholar
• Krause PR, Fleming TR, Longini IM, et al. SARS-CoV-2 variants and vaccines. N Engl J Med. 2021;385:179–186. doi:10.1056/NEJMsr2105280
   PubMed Web of Science ®Google Scholar
• Zhou H, Dcosta BM, Landau NR, et al. Resistance of SARS-CoV-2 omicron BA.1 and BA.2 variants to vaccine-elicited sera and therapeutic monoclonal antibodies. Viruses. 2022: 14.
   PubMedGoogle Scholar
• Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19:409–424. doi:10.1038/s41579-021-00573-0
   PubMed Web of Science ®Google Scholar
• Li Y, Ma ML, Lei Q, et al. Linear epitope landscape of the SARS-CoV-2 spike protein constructed from 1,051 COVID-19 patients. Cell Rep. 2021;34:108915. doi:10.1016/j.celrep.2021.108915
   PubMed Web of Science ®Google Scholar
• Zamecnik CR, Rajan JV, Yamauchi KA, et al. Rescan, a multiplex diagnostic pipeline, pans human sera for SARS-CoV-2 antigens. Cell Rep Med. 2020;1:100123. doi:10.1016/j.xcrm.2020.100123
   PubMedGoogle Scholar
• Ahmed SF, Quadeer AA, McKay MR. COVIDep: a web-based platform for real-time reporting of vaccine target recommendations for SARS-CoV-2. Nat Protoc. 2020;15:2141–2142. doi:10.1038/s41596-020-0358-9
   PubMed Web of Science ®Google Scholar
• Li Y, Lai DY, Zhang HN, et al. Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients. Cell Mol Immunol. 2020;17:1095–1097. doi:10.1038/s41423-020-00523-5
   PubMed Web of Science ®Google Scholar
• Yin D, Ling S, Tian X, et al. A single dose SARS-CoV-2 simulating particle vaccine induces potent neutralizing activities. bioRxiv. 2020. 2020.05.14.093054.
   Google Scholar
• Yi Z, Ling Y, Zhang X, et al. Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population. Emerg Microbes Infect. 2020;9:1988–1996. doi:10.1080/22221751.2020.1815591
   PubMed Web of Science ®Google Scholar
• Liu H, Wilson IA. Protective neutralizing epitopes in SARS-CoV-2. Immunol Rev. 2022;310:76–92. doi:10.1111/imr.13084
   PubMed Web of Science ®Google Scholar
• Guthmiller JJ, Wilson PC. Remembering seasonal coronaviruses. Science. 2020;370:1272–1273. doi:10.1126/science.abf4860
   PubMed Web of Science ®Google Scholar
• Ng KT, Mohd-Ismail NK, Tan YJ. Spike S2 subunit: the dark horse in the race for prophylactic and therapeutic interventions against SARS-CoV-2. Vaccines (Basel). 2021;9.
   Web of Science ®Google Scholar
• Chen Y, Zhao X, Zhou H, et al. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat Rev Immunol. 2022: 1–11.
   PubMed Web of Science ®Google Scholar